Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics reported progress in its CHM CDH17 clinical program, advancing to Dose Level 3 at 450 million CDH17 CART+ cells after early dose levels showed activity and a clean safety profile with no off-target effects. The company highlighted durable stable disease in two colorectal cancer patients and CAR T cell persistence in blood for up to 12 months, supporting confidence in the program’s risk profile and its path toward Phase 2 dose selection.
The company also disclosed that its CORE-NK Phase 1b trial, reported after quarter-end, achieved a 60% complete remission/complete remission with incomplete count recovery rate in 25 enrolled patients, underscoring potential efficacy of its NK platform. As part of a strategic reset, Chimeric streamlined its portfolio by returning the CHM CLTX program to City of Hope and refreshed leadership with the appointment of biotechnology specialist Dr. Bradley Glover as Non-Executive Chair and Aaron Laurita as Chief Financial Officer, aiming to sharpen focus and strengthen governance.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian clinical-stage cell therapy company focused on developing chimeric antigen receptor (CAR) and natural killer (NK) cell therapies for cancer. Listed on the ASX under the ticker CHM, the company targets solid and blood cancers, with a portfolio led by its CHM CDH17 CAR T program and the CORE-NK platform.
Average Trading Volume: 219,607
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
Learn more about CHM stock on TipRanks’ Stock Analysis page.